Company intelligence / Profile preview

BOLD Longevity Growth

Ownership: Private
Development stage: Other

Overview

BOLD Longevity Growth is a global longevity-focused venture capital fund investing in growth-stage biotech and health technology companies that address the root causes of aging and age-related disease. The team has backed innovations such as next-generation gene editing tools more efficient than CRISPR, AI-powered diagnostics/devices for cancer detection and surgery prediction, and advanced wearable health technologies. The firm’s mission is to make longevity technologies affordable and accessible worldwide[1][5].

Therapeutic areas: OtherOncologyNeurology
Modalities: Gene therapyMonoclonal antibodySmall moleculeAI-driven drug discoveryCell therapy
Industry: Investors

Partnerships

Co-invests with major biotech VC funds and large pharmaceutical firmsSupported by advisors from leading scientific institutions

Beyond the preview

Go deeper on BOLD Longevity Growth.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOLD Longevity Growth.

Explore the full profile